Cyhoeddiad
2023
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
Erthyglau
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
Contact Details
KitsonTC@caerdydd.ac.uk
+44 29206 87542
Neuadd Meirionnydd, Llawr 6, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
+44 29206 87542
Neuadd Meirionnydd, Llawr 6, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS